Brandes Investment Partners (AVDL) discloses 0.22% passive stake in Avadel
Rhea-AI Filing Summary
Brandes Investment Partners, L.P., a Delaware investment adviser, reports beneficial ownership of 218,835 common shares of Avadel Pharmaceuticals plc, equal to 0.22% of the class as of December 31, 2025. All voting and dispositive power over these shares is reported as shared, with no sole authority.
The filing is made on a passive Schedule 13G basis, with Brandes certifying that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Avadel.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Is Brandes Investment Partners’ stake in Avadel (AVDL) a passive investment?
Yes. Brandes certifies the shares were acquired and are held in the ordinary course of business. The filing states they are not held for the purpose of changing or influencing control of Avadel, consistent with a passive Schedule 13G filing.
What type of filer is Brandes Investment Partners in this Avadel (AVDL) Schedule 13G/A?
Brandes Investment Partners is identified as an investment adviser. The filing cites its status in accordance with Rule 13d-1(b)(1)(ii)(E), which covers institutional investment advisers reporting beneficial ownership on a Schedule 13G basis.
As of what date is Brandes’ Avadel (AVDL) ownership information reported?
The ownership information is reported as of December 31, 2025. That date is used as the event date requiring the Schedule 13G/A filing, anchoring the 218,835-share, 0.22% ownership figures disclosed by Brandes.